@mdpipharma.bsky.social🎯 NK cells engineered via #lipid-based #antibody capture—no #gene #modification! AC-NKs bind trastuzumab, T-DM1 & sacituzumab, enhancing cytotoxicity against #HER2+ & Trop-2+ #tumors. Scalable & programmable!
đź“Ś www.mdpi.com/1999-4923/17...
#Immunotherapy #NKcells #CancerResearch
@gbg.deWhat does a flamingo have to do with breast cancer research? More than you might think!
The #Flamingo-01 trial (#GBG111) is investigating an immunological treatment approach for patients with #HER2/neu-positive breast cancer and an increased risk of #recurrence.
@gbg.deA new analysis of the #Penelope-B clinical trial cohort, published in Modern Pathology, investigated #HER2 protein expression and mRNA profiles in 723 residual breast #cancer tumors following #neoadjuvant chemotherapy.
đź“„ Read the publication:
www.modernpathology.org/article/S089...
@ryvolution.bsky.socialHerceptin : Le MĂ©dicament qui a RĂ©volutionnĂ© le Cancer du SeinÂ
#Herceptin #Trastuzumab #CancerDuSein #HER2 #Cancer #Oncologie #OctobreRose #RYvolution
@ryvolution.bsky.socialCancer du Sein HER2+ : Plus Agressif, Mais Mieux Ciblé !
#CancerDuSein #HER2 #Cancer #Oncologie #OctobreRose #RYvolution
@agentictribune.bsky.socialFDA OKs Pfizer’s TUKYSA for Front‑line Maintenance in HER2‑Positive Metastatic Breast Cancer
@bionewscentral.comPatients with estrogen receptor–positive, #HER2 -negative advanced #BreastCancer experienced significantly longer progression-free survival when treated with an oral #CombinationTherapy that included #giredestrant, a next-generation selective #EstrogenReceptor degrader and complete antagonist.
@monalisarout1701.bsky.socialMethylcobalamin reduces severe hand-foot syndrome in HER2- breast cancer patients.
🧪 14.5% vs 29.1% incidence
📉 -14.5% risk difference
No specific AEs. #HER2 #Methylcobalamin
@newsen.bsky.socialBiocon's Pertuzumab: A Milestone Biosimilar Approved for HER2-Positive Breast Cancer #India #Bengaluru #Biocon #HER2-positive #Pertuzumab
@ipharmaservices.bsky.socialDESTINY-Lung04 : #Enhertu bat chimio+pembro en 1L #CBNPC HER2+
• SSP : 14,3 vs 8,3m
• TRG : 70% vs 44,5%
• SG : 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CancerDuPoumon #HER2
@ipharmaservices.bsky.socialDESTINY-Lung04: #Enhertu supera quimio+pembro en 1L #CPNM HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CáncerDePulmón #HER2
@mdpipharma.bsky.social🤔 Can one #nanoparticle deliver chemo + #targeted therapy + #antibody? This study co-loads docetaxel & neratinib + trastuzumab. Superior #tumor regression in #HER2+ models—first to combine all three!
👉 www.mdpi.com/1999-4923/17...
#BreastCancer #Nanoparticles #HER2 #DrugDelivery
@sneakyocto.bsky.socialThank you to #waifu.rachel and #Amethyst for reposting #mishamai_hime video on #Instagram. I'm sharing the #gofundme link in order to help gather support for her #breastcancer treatment. #krakenroyalty #snkyoctogaming #otakugamer #weeb #phuqcancer #her2 #youmatter gofund.me/cddb8c9be
@newsen.bsky.socialGroundbreaking Phase 3 Trial Reveals Benefits of Trastuzumab Deruxtecan in HER2-Mutant Lung Cancer #South_Korea #Seoul #Trastuzumab_Deruxtecan #HER2-Mutant_NSCLC #DESTINY-Lung04
@newsen.bsky.socialPromising Phase III Results of Trastuzumab Botidotin Offers Hope for HER2-Positive Breast Cancer Patients #China #Chengdu #Kelun-Biotech #HER2 #Trastuzumab_Botidotin
@rcatanho.bsky.socialTratamiento neoadyuvante con taxano, trastuzumab y pertuzumab alcanza la respuesta patológica completa en casi dos tercios de pacientes con cáncer de mama HER2+/ER- y un tercio con HER2+/ER+ #response #breastcancer #HER2+ ascopubs.org/doi/abs/10.1...